The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.
ASJC Scopus subject areas
the STAMPEDE investigators (2020). Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial (Ann Oncol (2019) 30 (1992–2003) (5574397)(10.1093/annonc/mdz396)). Annals of Oncology, 31(3). https://doi.org/10.1016/j.annonc.2020.01.002